CoChat

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19

Open access
Braendstrup, Peter, Levine, Bruce L., Ruella, Marco · 2020 · Cytotherapy
Cited by 150

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Thirty years after initial publications of the concept of a chimeric antigen receptor (CAR), the U.S. Food and Drug Administration (FDA) approved the first anti-CD19 CAR T cell therapy. Unlike other immunotherapies such as immune checkpoint inhibitors and bispecific antibodies, CAR T cells are unique as they are “living drugs”, i.e. gene-edited killer cells that can recognize and kill cancer. During these 30 years of development, the CAR construct, the T cell manufacturing process, and the clinical patient management went through rounds of failures and successes that drove continuous improvement. Tisagenlecleucel was the first gene therapy to receive approval from the FDA for any indication. The initial approval was for relapsed or refractory (r/r) pediatric and young-adult B-cell acute lymphoblastic leukemia in August 2017 and in May 2018 for adult r/r diffuse large B cell lymphoma. Here we review the pre-clinical and clinical development of what began as CART19 at the University of Pennsylvania and later developed into tisagenlecleucel.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcyt.2019.12.004

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 150

Metadata

Authors
Braendstrup, P., Levine, B. L., & Ruella, M.
Venue
Cytotherapy
Publisher
Elsevier BV
Published
2020-02
Volume
22
Issue
2
Pages
57-69
ISSN
1465-3249 (ISSN-L)
OpenAlex
W3004183788
Cited by
150
References
33
FWCI
5.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. https://app.cochat.ai/papers/10.1016/j.jcyt.2019.12.004
The paper
Braendstrup, P., Levine, B. L., & Ruella, M. (2020). The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. https://doi.org/10.1016/j.jcyt.2019.12.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.